Does a genotype-guided de-escalation strategy improve cost-effectiveness and QALYs compared to standard DAPT in patients with acute coronary syndrome?
A genotype-guided de-escalation strategy for DAPT in ACS patients is cost-saving and improves quality-adjusted life years compared to standard DAPT.
A genotype-guided de-escalation strategy in patients with ACS was both cost-saving and yielded higher QALYs compared to standard DAPT, highlighting its potential for implementation in clinical practice. Trial registration: ClinicalTrials.gov identifier: NCT03823547.
Broek et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: